{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:01:04Z","timestamp":1794571264163,"version":"4.9.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T00:00:00Z","timestamp":1744416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Krystal Biotech, Inc."},{"name":"Office of Research and Development at the Palo Alto Veterans Affairs Medical Center"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40257-025-00942-y","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T06:27:51Z","timestamp":1744439271000},"page":"623-635","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa"],"prefix":"10.1007","volume":"26","author":[{"given":"M. Peter","family":"Marinkovich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shireen V.","family":"Guide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes E.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne W.","family":"Lucky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u015f\u0131n Sinem","family":"Ba\u011fc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittani","family":"Agostini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kolleen","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan M.","family":"Conner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2163-0194","authenticated-orcid":false,"given":"Suma M.","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,12]]},"reference":[{"issue":"1","key":"942_CR1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41572-020-0210-0","volume":"6","author":"A Bardhan","year":"2020","unstructured":"Bardhan A, Bruckner-Tuderman L, Chapple ILC, et al. Epidermolysis bullosa. Nat Rev Dis Primers. 2020;6(1):78. https:\/\/doi.org\/10.1038\/s41572-020-0210-0.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"942_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/s0945-053x(98)00007-9","volume":"18","author":"L Bruckner-Tuderman","year":"1999","unstructured":"Bruckner-Tuderman L, Hopfner B, Hammami-Hauasli N. Biology of anchoring fibrils: lessons from dystrophic epidermolysis bullosa. Matrix Biol. 1999;18(1):43\u201354. https:\/\/doi.org\/10.1016\/s0945-053x(98)00007-9.","journal-title":"Matrix Biol"},{"key":"942_CR3","unstructured":"Marinkovich MP. Inherited epidermolysis bullosa. In: Kang S, Amagai M, Bruckner AL, et al (eds) Fitzpatrick\u2019s dermatology. Chapter 60. 9th ed. McGraw-Hill Education; 2019: p. 1011\u201335."},{"issue":"4","key":"942_CR4","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/bjd.18921","volume":"183","author":"C Has","year":"2020","unstructured":"Has C, Bauer JW, Bodemer C, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol. 2020;183(4):614\u201327. https:\/\/doi.org\/10.1111\/bjd.18921.","journal-title":"Br J Dermatol"},{"key":"942_CR5","doi-asserted-by":"publisher","first-page":"933","DOI":"10.2147\/CCID.S232547","volume":"12","author":"S Eichstadt","year":"2019","unstructured":"Eichstadt S, Tang JY, Solis DC, et al. From clinical phenotype to genotypic modelling: incidence and prevalence of recessive dystrophic epidermolysis bullosa (RDEB). Clin Cosmet Investig Dermatol. 2019;12:933\u201342. https:\/\/doi.org\/10.2147\/CCID.S232547.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"5","key":"942_CR6","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/bjd.20958","volume":"186","author":"G Petrof","year":"2022","unstructured":"Petrof G, Papanikolaou M, Martinez AE, et al. The epidemiology of epidermolysis bullosa in England and Wales: data from the national epidermolysis bullosa database. Br J Dermatol. 2022;186(5):843\u20138. https:\/\/doi.org\/10.1111\/bjd.20958.","journal-title":"Br J Dermatol"},{"issue":"11","key":"942_CR7","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1001\/jamadermatol.2016.2473","volume":"152","author":"JD Fine","year":"2016","unstructured":"Fine JD. Epidemiology of inherited epidermolysis bullosa based on incidence and prevalence estimates from the National Epidermolysis Bullosa Registry. JAMA Dermatol. 2016;152(11):1231\u20138. https:\/\/doi.org\/10.1001\/jamadermatol.2016.2473.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"942_CR8","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/jdv.18637","volume":"37","author":"C Has","year":"2023","unstructured":"Has C, Hess M, Anemuller W, et al. Epidemiology of inherited epidermolysis bullosa in Germany. J Eur Acad Dermatol Venereol. 2023;37(2):402\u201310. https:\/\/doi.org\/10.1111\/jdv.18637.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"942_CR9","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.jid.2018.11.036","volume":"139","author":"MP Marinkovich","year":"2019","unstructured":"Marinkovich MP, Tang JY. Gene therapy for epidermolysis bullosa. J Invest Dermatol. 2019;139(6):1221\u20136. https:\/\/doi.org\/10.1016\/j.jid.2018.11.036.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"942_CR10","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13023-022-02509-0","volume":"17","author":"JA Feinstein","year":"2022","unstructured":"Feinstein JA, Bruckner AL, Chastek B, et al. Clinical characteristics, healthcare use, and annual costs among patients with dystrophic epidermolysis bullosa. Orphanet J Rare Dis. 2022;17(1):367. https:\/\/doi.org\/10.1186\/s13023-022-02509-0.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"942_CR11","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41591-022-01737-y","volume":"28","author":"I Gurevich","year":"2022","unstructured":"Gurevich I, Agarwal P, Zhang P, et al. In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial. Nat Med. 2022;28(4):780\u20138. https:\/\/doi.org\/10.1038\/s41591-022-01737-y.","journal-title":"Nat Med"},{"key":"942_CR12","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa2206663","volume":"387","author":"SV Guide","year":"2022","unstructured":"Guide SV, Gonzalez ME, Bagci S, et al. Trial of beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa. N Engl J Med. 2022;387:2211\u20139. https:\/\/doi.org\/10.1056\/NEJMoa2206663.","journal-title":"N Engl J Med"},{"key":"942_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1477-7525-2-12","volume":"2","author":"MJ Atkinson","year":"2004","unstructured":"Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the treatment satisfaction questionnaire for medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12. https:\/\/doi.org\/10.1186\/1477-7525-2-12.","journal-title":"Health Qual Life Outcomes"},{"key":"942_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1477-7525-7-36","volume":"7","author":"M Bharmal","year":"2009","unstructured":"Bharmal M, Payne K, Atkinson MJ, et al. Validation of an abbreviated treatment satisfaction questionnaire for medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes. 2009;7:36. https:\/\/doi.org\/10.1186\/1477-7525-7-36.","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"942_CR15","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/1523-1747.ep12365600","volume":"107","author":"MM Chren","year":"1996","unstructured":"Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1996;107(5):707\u201313. https:\/\/doi.org\/10.1111\/1523-1747.ep12365600.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"942_CR16","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.det.2011.11.003","volume":"30","author":"MM Chren","year":"2012","unstructured":"Chren MM. The Skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin. 2012;30(2):231\u20136. https:\/\/doi.org\/10.1016\/j.det.2011.11.003.","journal-title":"Dermatol Clin"},{"issue":"1","key":"942_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-019-1279-y","volume":"15","author":"AL Bruckner","year":"2020","unstructured":"Bruckner AL, Losow M, Wisk J, et al. The challenges of living with and managing epidermolysis bullosa: insights from patients and caregivers. Orphanet J Rare Dis. 2020;15(1):1. https:\/\/doi.org\/10.1186\/s13023-019-1279-y.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"942_CR18","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1038\/jid.2011.138","volume":"131","author":"CAC Prinsen","year":"2011","unstructured":"Prinsen CAC, Lindeboom R, de Korte J. Interpretation of Skindex-29 scores: cutoffs for mild, moderate, and severe impairment of health-related quality of life. J Invest Dermatol. 2011;131(9):1945\u20137. https:\/\/doi.org\/10.1038\/jid.2011.138.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"942_CR19","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s13023-022-02419-1","volume":"17","author":"A Angelis","year":"2022","unstructured":"Angelis A, Mellerio JE, Kanavos P. Understanding the socioeconomic costs of dystrophic epidermolysis bullosa in Europe: a costing and health related quality of life study. Orphanet J Rare Dis. 2022;17(1):346. https:\/\/doi.org\/10.1186\/s13023-022-02419-1.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"942_CR20","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.det.2010.01.004","volume":"28","author":"JE Mellerio","year":"2010","unstructured":"Mellerio JE. Infection and colonization in epidermolysis bullosa. Dermatol Clin. 2010;28(2):267\u20139. https:\/\/doi.org\/10.1016\/j.det.2010.01.004.","journal-title":"Dermatol Clin"},{"issue":"4","key":"942_CR21","doi-asserted-by":"publisher","first-page":"9700","DOI":"10.4081\/dr.2023.9700","volume":"15","author":"A Alheggi","year":"2023","unstructured":"Alheggi A, Alnutaifi R, Alkhonezan M, et al. Measuring the impact of pruritus in patients with epidermolysis bullosa: evaluation with an itch-specific instrument. Dermatol Rep. 2023;15(4):9700. https:\/\/doi.org\/10.4081\/dr.2023.9700.","journal-title":"Dermatol Rep."},{"issue":"5","key":"942_CR22","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.jaad.2012.01.016","volume":"67","author":"E Pope","year":"2012","unstructured":"Pope E, Lara-Corrales I, Mellerio J, et al. A consensus approach to wound care in epidermolysis bullosa. J Am Acad Dermatol. 2012;67(5):904\u201317. https:\/\/doi.org\/10.1016\/j.jaad.2012.01.016.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"942_CR23","doi-asserted-by":"publisher","first-page":"641","DOI":"10.18609\/cgti.2022.096","volume":"8","author":"T Parry","year":"2022","unstructured":"Parry T, Prosdocimo DA, Krishnan S. A new era of in vivo gene therapy: the applicability of a differentiated HSV-1 based vector platform for redosable medicines. Cell Gene Ther Insights. 2022;8(5):641\u201351. https:\/\/doi.org\/10.18609\/cgti.2022.096.","journal-title":"Cell Gene Ther Insights."}],"updated-by":[{"DOI":"10.1007\/s40257-025-00956-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000}}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00942-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00942-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00942-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T08:17:56Z","timestamp":1751617076000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00942-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,12]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["942"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00942-y","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40257-025-00956-6","asserted-by":"object"}]},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,12]]},"assertion":[{"value":"17 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40257-025-00956-6","URL":"https:\/\/doi.org\/10.1007\/s40257-025-00956-6","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Krystal Biotech (ClinicalTrials.gov Identifier: NCT04917874). The study sponsors participated in the study design; the collection, analysis, and interpretation of the data; the writing of the report; and the decision to submit the article for publication. M. Peter Marinkovich also received funding from the Office of Research and Development at the Palo Alto Veterans Affairs Medical Center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"M. Peter Marinkovich has undertaken paid consultancy for Amryt Pharmaceuticals DAC, is a consultant and speaker for Krystal Biotech, and is an investigator for Abeona, Castle Creek Biosciences, and Krystal Biotech, through funding administered by Stanford University Office of Sponsored Research. Amy S. Paller has been an investigator for AbbVie, Arcutis, Dermavant, Eli Lilly, Incyte, Janssen, Krystal Biotech, and UCB; a consultant for BioCryst, Boehringer-Ingelheim, Bristol Myers Squibb, Dermavant, Johnson & Johnson, Krystal Biotech, LEO Pharma, Mitsubishi Tanabe Pharma, Novartis, Primus Pharmaceuticals, Procter and Gamble, Regeneron, Sanofi\/Genzyme, TWI Biotechnology, and UCB; and is on the data safety monitoring board for AbbVie, Abeona, Catawba, and Galderma. Amy S. Paller is an Editorial Board member of the American Journal of Clinical Dermatology; she was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Shireen V. Guide has been an investigator for Arcutis, Boehringer-Ingelheim, Castle Biosciences, Dermavant, Incyte, Jeune, Krystal Biotech, Novartis, Pfizer, and Sanofi, and a consultant and speaker for Krystal Biotech. Mercedes E. Gonzalez has been an investigator for AbbVie, Arcutis, Amgen, Anterogen, Dermavant, Eli Lilly, Incyte, Krystal Biotech, Neilsen Biosciences, Novartis, Regeneron, and Sanofi; a consultant with honorarium for Abeona, Apogee, Arcutis, Alphyn, Dermavant, Eli Lilly, Incyte, Krystal Biotech, and Verrica Pharmaceuticals, and on the speaker\u2019s bureau for Verrica Pharmaceuticals, Regeneron, Sanofi, Genzyme, Eli Lilly, Abbvie, Pfizer, and Krystal Biotech. Anne W. Lucky has been an investigator for Krystal Biotech and Phoenicis. I\u015f\u0131n Sinem Ba\u011fc\u0131 has been an investigator for Castle Creek Biosciences and Krystal Biotech. Brittani Agostini, Kolleen Fitzgerald, Meghan M. Conner, and Suma M. Krishnan are employees and shareholders of Krystal Biotech. Shijie Chen and Hubert Chen were employees and shareholders of Krystal Biotech at the time of the analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study was performed in accordance with the Declaration of Helsinki, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice guidelines, and other applicable laws and regulations. Approval was obtained from the Stanford University Administrative Panel on Human Subjects in Medical Research (Site 1), Advarra (Sites 2 and 3), the Cincinnati Children\u2019s Institutional Review Board (Site 4), and the Ann & Robert H. Lurie Children\u2019s Hospital of Chicago Institutional Review Board (Site 5).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants gave written informed consent\/assent to participate in the research. At least one parent or guardian for each adolescent patient provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Patients signed an informed consent regarding publishing their data and photographs.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All requests for data will be reviewed by the clinical sites and the study sponsor, Krystal Biotech, to verify whether the request is subject to any intellectual property or confidentiality obligations. Requests for access to the patient-level data from this study can be submitted via e-mail to medinfo@krystalbio.com with detailed proposals for approval. A signed data access agreement with the sponsor is required before accessing shared data.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors meet the International Committee of Medical Journal Editors criteria for authorship of this article. Study conception and design: SMK and HC; acquisition, analysis, and interpretation of data: MPM, ASP, SVG, MEG, AWL, and ISB; analysis of data: SC; supervision: SMK and BA; technical support: KF; formal analysis and writing (original draft preparation): MMC. All authors contributed to the critical revision of the manuscript for important intellectual content and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}